References
- Lokich J. Improving 5-Fluorouracil biomodulation, pharmaco-modulation or infusional administration schedules. Cancer Invest 1998; 16: 293–294
- Iyer L, Ratain M S. 5-Fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest 1999; 17: 494–506
- Glimelius Jakobsen B. A, Graf W. Bolus injection (2–4 min) versus short-term (10–20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomized trial. Eur J Cancer 1998; 34: 674–678
- Sohrero A F, Aschele C, Bertino J R. Fluorouracil in colorectal cancer—a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997; 15: 368–381
- Findlay M, Van Cutsem E, Kocha W. A randomized phase II study of XelodaTM (capecitabine) in patients with advanced colorectal cancer. PASCO 1997; 16: 798
- Pazdur R, Lassere Y, Rhodes V. Phase II trial of uracil and tagafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994; 12: 2296–2300
- Ahlgren J D. Protracted infusional schedules of fluorouracil in colorectal cancer versus fluorouracil with modulators: differences and similarities. J Infus Chemother 1992; 2: 28–137
- Leichman C G, Leichman L, Spears C P. Biological modification of protracted infusion of 5-fluorouracil with weekly leucovorin. A dose seeking clinical trial for patients with disseminated gastrointestianal cancers. Cancer Chemother Pharmacol 1990; 26: 57–61
- Tempero M, Mitchell M, Higginbotham P. Tolerance of protracted infusion 5-fluorouracil and oral laucovorin. Proc Annu Meet Am Soc Clin Oncol 1991; 10: 160, abstract
- Lokich J J, Anderson N R, Bern M M. A phase I clinical trial of combined fluoropyrimidines with leucovorin in 14-day infusion. Cancer 1989; 63: 233–237